Health

Study targets role of anti-inflammatory drug in fighting diabetes

New research will test the long-term safety and efficacy of a NSAID at reining in out-of-control blood glucose levels.

By Susan J. Landers — Posted Feb. 24, 2009

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

Researchers are embarking on a multicenter study that targets inflammation as a way to reduce blood glucose levels in people with type 2 diabetes.

If treatment with salsalate, an anti-inflammatory drug used for years to manage arthritis pain, is successful, it could lead to an effective, inexpensive way to treat the most common form of diabetes, the researchers say.

Investigators from 20 medical centers across the country are seeking 560 adults ages 18 to 75 whose glucose levels are not well controlled. Participants may be taking as many as two oral medications but not insulin.

Entry criteria and a listing of study sites for the Targeting Inflammation with Salsalate in Type 2 Diabetes, or TINSAL-T2D, trial can be found online (link).

The study is being funded by the National Institute of Diabetes and Digestive and Kidney Diseases and is a follow-up to promising results of earlier NIDDK-funded studies at the Joslin Diabetes Center in Boston.

That study found blood sugar levels were lowered when salsalate was given for three months. Now researchers want to determine if the drug will be well tolerated and effective over a longer period.

"Given what we've learned about the role of inflammation in the development of type 2 diabetes, this therapy might be getting at an underlying cause of the disease," said principal investigator Steven E. Shoelson, MD, PhD, associate director of research at Joslin and professor of medicine at Harvard Medical School.

Salsalate, a nonsteroidal anti-inflammatory drug, is approved by the Food and Drug Administration to relieve mild to moderate pain, fever, arthritis and other musculoskeletal conditions.

As with all other NSAIDs, salsalate carries a black-box warning for elevating risk for heart attacks and strokes. It also increases the risk of ulcers and stomach bleeding. The prescription drug has been used for decades.

"The outcome of this study has the potential for significant public health benefit," said Myrlene Staten, MD, NIDDK's senior adviser for diabetes translational research. "If salsalate improves the control of type 2 diabetes, we would have a much-needed, inexpensive addition to our arsenal of drug options."

Diabetes' toll on the nation's health has been soaring in recent years because of the obesity epidemic. Type 2 diabetes often leads to complications, including cardiovascular disease, blindness, kidney disease and amputations. People with diabetes die at rates two to four times higher than those who do not have it, according to NIDDK data.

Back to top


ADVERTISEMENT

ADVERTISE HERE


Featured
Read story

Confronting bias against obese patients

Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story


Read story

Goodbye

American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story


Read story

Policing medical practice employees after work

Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story


Read story

Diabetes prevention: Set on a course for lifestyle change

The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story


Read story

Medicaid's muddled preventive care picture

The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story


Read story

How to get tax breaks for your medical practice

Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story


Read story

Advance pay ACOs: A down payment on Medicare's future

Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story


Read story

Physician liability: Your team, your legal risk

When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story

  • Stay informed
  • Twitter
  • Facebook
  • RSS
  • LinkedIn